Tag: avxl

Anavex to Participate in Mizuho Therapeutics Conference

NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…

Anavex Reports Fiscal Third Quarter 2016 Financial Results

NEW YORK, Aug. 11, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and…

Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016

NEW YORK, July 29, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73. Dr. Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented:  “To…

Anavex Presents New Data on Preclinical Development of ANAVEX 3-71

NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71…

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Anavex Life Sciences Corp. and a Lead Plaintiff Deadline of February 29, 2016 – AVXL

NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) — The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015. Click here…

The Buzz on $AVXL – #Anavex – Investigation, Discovery & Shareholders!

I’m sure you all know that we have covered Anavex Holdings $AVXL since at least May. Likely before most of you ever heard of it. We’ve never held a position and we’ve never been compensated. We followed it for the upside we saw, as this stock was heavily promoted. Now, we see the downside as kicking…

News $AVXL – #Anavex Reports Fiscal First Quarter 2016 Financial Results
Huge News $AVXL – #Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. and Certain Officers – AVXL

NEW YORK, Dec. 30, 2015 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”)(NASDAQ:AVXL), and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 15-cv-10162, is on behalf of…

Trade Alert: Price for $RXSF Creates Potential Upside Gain of 161% if Reaches 5-Day High Again

Anavex Announces Fiscal 2015 Year-End Financial Results

NEW YORK, Dec. 29, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported year-end results for fiscal year 2015. Financial Highlights:…

The Buzz is Positive on $AVXL as it Continues to Hold Most of the Early Gains

Anavex Expands Management Team

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Ulrich Elben, PhD as Vice…

Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer’s Disease Models

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer, announced today the publication of further data for ANAVEX…

The Buzz is Growing as $AVXL Moves Higher, Reversing the Trend

Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program…

Anavex Announces CTAD 2015 Abstract

NEW YORK, Nov. 05, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is pleased to announce that the abstract for its presentation of full PART A data…

The Buzz only Get’s Bigger as $AVXL is now on Nasdaq and the Price Closes in on $15!

Anavex Life Sciences Corp. (Nasdaq:AVXL) to Ring The Nasdaq Stock Market Closing Bell

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] ADVISORY, Oct. 29, 2015 (GLOBE NEWSWIRE) — What:  Anavex Life Sciences Corp. (Nasdaq:AVXL), a clinical-stage biopharmaceutical company that is developing drug candidates for Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, will visit the Nasdaq MarketSite in Times Square to celebrate its recent listing…

Buzz on $AVXL $AVXLD – Is StockGuru Behind This Momentum? Find Out Here!  #ANAVEX